Ling Su, Ph.D., is a Venture Partner with Lilly Asia Ventures (LAV). Prior to joining LAV, He has over 25 years’ experience in drug regulatory and development. He had worked in various R&D management positions in the pharma industry, including Medical Director at Merck, Pharma Development Director at Roche, VP for Clinical Research Asia Pacific at Wyeth, and SVP and Head of Development China at Novartis. Prior to that, he worked in the Chinese regulatory agency and CDER, US FDA. Currently, Ling is also a professor in Regulatory Science in Shenyang Pharmaceutical University and serves as an advisor to the Chinese regulatory agency on numerous projects. He is a member of the Hong Kong Stock Exchange Biotech Advisory Panel. Ling holds B.S. in pharmacology from Shanghai Medical University, M.S. in Clinical Pharmacy and Ph.D. in Epidemiology from University of North Carolina at Chapel Hill, USA.